Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 6 2 2012 06 15 32 34 Nasim Valizadeh Department of Hematology/Medical Oncology, Urmia University of Medical Sciences, Urmia, Iran Rahim Nejad Rahim Department of Infectious Disease, Urmia University of Medical Sciences, Urmia, Iran Shahin Nateghi Medical Student, Departmen of Medicine, Urmia University of Medical Sciences, Urmia, Iran 2015 10 01 Patients with lymphoproliferative disorders have cellular immune deficiency and are susceptible to typical and atypical mycobacterial infections.Hairy cell leukemia is a B-cell type lymphoproliferative disorder.2-CDA is the choice of treatment for patients with hairy cell leukemia. It is a synthetic antineoplastic agent with immunosuppressive effects.We present development of pulmonary and meningeal TB in a case of hairy cell leukemia 8 months after treatment with 2-CDA. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/334 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/334/320